This site is intended for UK healthcare professionals.

This promotional meeting has been organised and funded by the BMS/Pfizer Alliance

Implementing anticoagulation recommendations for stroke prevention in NVAF

Next event starting shortly

About the webinar


An interactive discussion on anticoagulation recommendations for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), and approaches taken in primary care to improve adherence to guideline recommended prescribing of anticoagulation therapy. The audience will learn about guideline recommendations and approaches that can be taken in primary care to identify patients with NVAF who are not receiving guideline-recommended anticoagulation for stroke prevention, helping to ensure that patients receive appropriate treatment to decrease their stroke risk, where indicated.

For Prescribing and Adverse Event reporting information, click here

From the experts


Dr Youssef Beaini

Primary Care Physician, CVD Lead for Bradford, Airedale, Wharfedale and Craven CCGs

Dr Beaini qualified 23 years ago and spent his first 10 years in hospital medicine, 5 1/2 years of which was training in hospital cardiology. He then decided to move over the General Practice. After taking up partnership at the Ridge Medical Practice, he soon got involved with CCG-wide quality improvement projects in CVD. The Bradford’s Healthy Hearts programme achieved over 24,000 improvements to patients’ care over a four year period with little impact on primary care workload, improving care in lipids, hypertension, atrial fibrillation and more recently in heart failure. It was estimated that in the first 15 months of the programme, there were 211 fewer heart attacks and strokes in the CCG, saving £1.2m. He was part of the small team that won the BMJ award in 2016 for clinical leadership for that programme. Dr Beaini then became clinical lead for the roll out of a similar programme across the West Yorkshire STP/ICS, the “West Yorkshire’s Healthy Hearts programme”. This programme resulted in improvements to the blood pressure care of 27,500 people in the first 12 months with little impact on primary care workload, winning the HSJ Value award for cardiovascular initiative of the year, 2020. The third phase of the West Yorkshire Healthy Hearts programme will address the CVD risk in diabetics specifically. Dr Beaini has recently taken up the role of primary care clinical lead for the National NHS England lipid programme under the Rapid Uptake Products initiative and the NHS Accelerated Access Collaborative. He has recently been appointed national clinical lead for education for the wider National Lipids Programme for the Academic Health Science Networks, NHS England, and the Accelerated Accelerated Access Collaborative. He is part of NHS England’s national CVD leadership group.

Ketan Kavia

Pharmacist Advanced Clinical Practitioner, CardioMetaBology

Ketan Kavia trained as a Pharmacist at DeMontfort University, where he later returned to complete a post-graduate qualification in Advanced Practice in Urgent Primary Care. He has a specialist interest in cardio-metabolic medicine and a passion for delivering educational training sessions for GPs and Allied healthcare professionals both at National and European level.

Ketan has worked extensively in the area of cardiovascular and metabolic medicine with a proven track record of deliverable outcomes. His passion lies in reducing health inequalities and is truly committed to supporting the NHS long term plan around cardiovascular disease management. His passion and drive comes from his experience of working in General Practice and up-skilling teams of Allied healthcare professionals in the management of long term conditions. His collaboration between relevant organisations within the NHS and the Pharmaceutical industry has supported him to deliver innovation in the area of cardio-metabolic medicine. Medical research and publications have become an integral part of his career to share both knowledge and experience to the wider healthcare community.

Adverse events should be reported.
Reporting forms and information can be found at: UK –, or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via or 0800 731 1736 (UK)

This promotional meeting has been organised and funded by the BMS/Pfizer Alliance

PP-ELI-GBR-8220 | April 2021